Thalidomide and Dexamethasone: A New Standard of Care for Initial Therapy in Multiple Myeloma
- 20 January 2006
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 24 (3) , 334-336
- https://doi.org/10.1200/jco.2005.03.8851
Abstract
InthisissueoftheJournalofClinicalOncology,Rajkumaretal report on the results of a randomized phase III clinical trial of thalidomide plus dexamethasone compared to high-dose dexa- methasone alone in newly diagnosed multiple myeloma. 1 In this study, coordinated by the Eastern Cooperative Oncology Group, 207 patients were randomly assigned to either thalidomide plus dexamethasoneorhigh-dosedexamethasonealone.Responserate, the primary end point, was significantly higher with thalidomide plus dexamethasone than single-agent high-dose dexamethasone (63% v 41%, respectively, P.002); however, this benefit was associated with important toxicities, including deep vein throm- bosis (DVT) and treatment-related mortality, which were 5% and 4%, respectively. 1Keywords
This publication has 21 references indexed in Scilit:
- Phase III Clinical Trial of Thalidomide Plus Dexamethasone Compared With Dexamethasone Alone in Newly Diagnosed Multiple Myeloma: A Clinical Trial Coordinated by the Eastern Cooperative Oncology GroupJournal of Clinical Oncology, 2006
- Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myelomaBlood, 2005
- PAD combination therapy (PS‐341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myelomaBritish Journal of Haematology, 2005
- Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myelomaBritish Journal of Haematology, 2005
- Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivoLeukemia, 2003
- Thalidomide Alone or With Dexamethasone for Previously Untreated Multiple MyelomaJournal of Clinical Oncology, 2003
- Molecular mechanisms of novel therapeutic approaches for multiple myelomaNature Reviews Cancer, 2002
- Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myelomaBlood, 2002
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999
- VAD‐based regimens as primary treatment for multiple myelomaAmerican Journal of Hematology, 1990